Alzheimer’s disease, a progressive neurodegenerative disorder, affects an estimated 6.9 million Americans aged 65 and older, and over 55 million people worldwide live with dementia, with Alzheimer’s being the most common cause. Beyond its profound impact on cognitive functions such as memory, thinking, and reasoning, Alzheimer’s often manifests in a range of neuropsychiatric symptoms that significantly diminish quality of life for both patients and their caregivers. Among the most distressing and challenging of these symptoms is agitation, which affects approximately three-quarters of individuals living with the disease.<\/p>\n
Agitation in Alzheimer’s patients can encompass a wide spectrum of behaviors, ranging from restless pacing, repetitive movements, and general unease to more severe manifestations such as verbal aggression, yelling, cursing, and even physical lashing out at others. These behaviors are not merely inconvenient; they are deeply distressing, disruptive, and can lead to serious consequences. For patients, agitation can exacerbate cognitive decline, impair sleep, and increase the risk of falls or injury. For caregivers, the relentless nature of agitation often results in immense emotional, physical, and financial strain, contributing to caregiver burnout, depression, and a higher likelihood of placing loved ones in assisted living or long-term care facilities. Indeed, experts like Jeffrey Cummings, MD, a professor at the Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas, emphasize that agitation is "among the most burdensome aspects of the disease for patients and families," and is "associated with accelerated cognitive decline, placement in assisted living and long-term care facilities, and increased mortality risk."<\/p>\n
Historically, treatment options for Alzheimer’s-related agitation have been severely limited, often relying on off-label use of antipsychotic medications. While these drugs can sometimes alleviate symptoms, they carry a "black box warning" \u2013 the FDA’s most stringent safety warning \u2013 for elderly patients with dementia-related psychosis due to an increased risk of death. Other side effects can include sedation, cognitive dulling, and cardiovascular issues, further complicating care and often compromising the patient’s remaining cognitive abilities and overall well-being. This creates a critical unmet medical need for safer, more targeted interventions.<\/p>\n
Auvelity’s Novel Mechanism: A Different Approach<\/strong><\/p>\n Developed by Axsome Therapeutics, Auvelity, previously known as AXS-05, is a combination of two established compounds: dextromethorphan (DM), an NMDA receptor antagonist and sigma-1 receptor agonist, and bupropion, an aminoketone antidepressant that also inhibits the reuptake of dopamine and norepinephrine, and acts as an enzyme inhibitor, which increases the bioavailability of dextromethorphan. This unique dual-action mechanism is designed to modulate the activity of two specific brain cell receptors: the N-methyl-D-aspartate (NMDA) receptor and the sigma-1 receptor.<\/p>\n The NMDA receptor plays a crucial role in learning and memory, and its dysregulation is implicated in various neurological and psychiatric conditions, including Alzheimer’s disease. By modulating NMDA receptor activity, Auvelity aims to restore a more balanced neuronal function. Concurrently, the sigma-1 receptor is involved in a wide range of cellular processes, including neuronal protection, plasticity, and neurotransmitter regulation. Activation of the sigma-1 receptor has been linked to antidepressant and anxiolytic effects. This synergistic action allows Auvelity to address the underlying neurobiology of agitation in Alzheimer’s without the broad, less specific effects associated with antipsychotics.<\/p>\n Significantly, Auvelity received its initial FDA approval in August 2022 for the treatment of major depressive disorder (MDD) in adults. This prior approval provides a foundation of safety and efficacy data for the drug combination, which was leveraged in its development for the Alzheimer’s agitation indication. The approval for Alzheimer’s-related agitation expands its utility into a population desperate for better options, positioning it as a significant advancement in neuropsychiatric care for neurodegenerative diseases.<\/p>\n Rigorous Clinical Validation: Evidence from Pivotal Trials<\/strong><\/p>\n Axsome Therapeutics’ application for FDA approval of Auvelity for Alzheimer’s-related agitation was supported by a comprehensive battery of clinical trials, including four Phase 3 studies: ACCORD (NCT04797715), ACCORD-2 (NCT04947553), ADVANCE-1 (NCT03226522), and ADVANCE-2 (NCT05557409), along with an extension study (NCT06736509) monitoring long-term outcomes. These trials collectively demonstrated Auvelity’s efficacy and a favorable safety profile.<\/p>\n The ACCORD and ACCORD-2 studies employed a relapse-prevention design, a robust methodology for evaluating long-term treatment effects. In these studies, all participants initially received Auvelity. Those who experienced a substantial reduction in agitation, as measured by the Cohen-Mansfield Agitation Inventory (CMAI) \u2013 a widely recognized standardized tool for assessing the frequency and severity of agitated behaviors \u2013 were then randomized to either continue active therapy with Auvelity or switch to a placebo. The results from both studies were compelling: patients who switched to a placebo were significantly more likely to experience recurring agitation compared to those who continued taking Auvelity. George Grossberg, MD, a professor at the Saint Louis University School of Medicine, noted the significance of these findings, stating, "Auvelity is the only FDA-approved product to result in a statistically significantly longer time to relapse of agitation symptoms, compared to placebo, in a long-term study." This data provides critical evidence of Auvelity’s sustained benefit in preventing the recurrence of agitated episodes.<\/p>\n The ADVANCE-1 and ADVANCE-2 studies, conversely, directly compared Auvelity against a placebo in patients with Alzheimer’s-related agitation. In the smaller ADVANCE-1 study, Auvelity demonstrated statistically significant superiority over placebo in reducing agitation, again measured by CMAI scores. The larger ADVANCE-2 study also showed that patients receiving Auvelity tended to report reductions in agitation compared with those on placebo. While this difference in ADVANCE-2 did not reach statistical significance (meaning the probability that this observed difference was due to random chance was non-negligible, though a positive trend was evident), the totality of the clinical evidence, particularly the strong relapse prevention data, supported the overall efficacy profile.<\/p>\n Importantly, across all clinical trials, Auvelity exhibited a compelling safety and tolerability profile. Rates of discontinuation due to adverse events were low and consistent with those observed in the placebo groups, suggesting that the medication is generally well-tolerated by the target patient population. The most commonly reported side effects in Alzheimer’s patients were dyspepsia (indigestion) and dizziness. As with many medications approved to treat depression, the prescribing information for Auvelity includes a black box warning concerning an increased risk of suicidal thoughts and behaviors in young people, which is a standard regulatory requirement for antidepressants. However, it’s crucial to contextualize this for an elderly Alzheimer’s population, where this specific risk profile differs from that in younger individuals. The overall safety data from the trials was reassuring for the target demographic.<\/p>\n Voices from the Community: Expert and Advocacy Reactions<\/strong><\/p>\n The approval of Auvelity has been met with widespread acclaim from patient advocacy groups, medical professionals, and the pharmaceutical industry, underscoring the profound need for this new treatment option.<\/p>\n Joanne Pike, president and CEO of the Alzheimer’s Association, encapsulated the long-standing frustration and the newfound hope, stating in a press release, "For too long, people living with Alzheimer’s disease agitation and their families have had limited options, and the options that existed came with significant risks. This approval gives patients, caregivers and clinicians an important new tool \u2013 one that works through a different mechanism than antipsychotic medications and that can help address a symptom that profoundly affects quality of life for people living with Alzheimer’s and those who care for them." Her remarks highlight the dual benefit of efficacy and a safer profile, which has been a critical missing piece in Alzheimer’s care.<\/p>\n Herriot Tabuteau, MD, CEO of Axsome Therapeutics, echoed this sentiment, emphasizing the milestone for the millions affected by the disease. "The approval of our first-in-class medication for agitation associated with Alzheimer’s disease marks an important milestone for the millions of patients living with Alzheimer’s disease, their families, and their caregivers. We are very pleased to deliver to clinicians and patients a new, effective, FDA-approved treatment option, with a distinct mechanism of action, for this debilitating and critically underserved condition," he stated in a company press release. His statement underscores Axsome’s commitment to addressing complex neuropsychiatric conditions with innovative solutions.<\/p>\n Leading researchers in the field also lauded the approval. Dr. Jeffrey Cummings further elaborated on the severity of agitation, noting its impact on patient prognosis and the historical lack of effective treatments. He concluded that Auvelity "has the potential to play an important role in patient care for this challenging and impactful symptom of Alzheimer’s disease." Dr. George Grossberg reiterated the importance of the safety profile, stating, "Importantly, Auvelity showed a compelling safety and tolerability profile, with rates of discontinuation due to adverse events that were low and matched those of placebo. The approval of Auvelity is a significant advancement that provides patients and their caregivers with a much-needed treatment option for this debilitating condition."<\/p>\n Adding a broader perspective, Frank Longo, MD, PhD, a professor of neurology at Stanford University and co-founder of Pharmatrophix, a company developing new Alzheimer’s treatments, remarked that the FDA’s approval "highlights the advances being made in addressing the day-to-day realities of the disease." He further commented, "For patients and caregivers, any progress in Alzheimer’s treatment is meaningful. This milestone\u2026 reflects the growing momentum in innovative treatments for neurodegenerative diseases and further underscores the continued need for disease-modifying therapies."<\/p>\n Broader Implications: Transforming Care and Future Prospects<\/strong><\/p>\n The FDA approval of Auvelity for Alzheimer’s-related agitation carries profound implications that extend beyond the immediate relief for patients. It represents a significant paradigm shift in how behavioral symptoms of dementia can be managed, potentially transforming patient care, reducing caregiver burden, and influencing the broader healthcare landscape.<\/p>\n Impact on Patients and Caregivers:<\/strong> For patients, the ability to manage agitation effectively without the heavy sedation or significant adverse effects of antipsychotics can dramatically improve their quality of life. Reduced agitation can lead to better sleep, less distress, and potentially a greater ability to engage in daily activities and social interactions. For caregivers, this approval offers a beacon of hope, promising a reduction in the emotional and physical toll associated with managing severe agitation. By mitigating disruptive behaviors, Auvelity could enable patients to remain in their homes longer, delaying or preventing institutionalization and preserving the family unit. The patient support program, Auvelity OnMySide, which Axsome plans to launch concurrently with the medication, will provide crucial resources, including financial aid and insurance assistance, for eligible patients, further easing the burden of access and cost.<\/p>\n Healthcare System Impact:<\/strong> From a public health perspective, the widespread adoption of Auvelity could lead to a reduction in healthcare utilization related to agitation. This includes fewer emergency room visits, hospitalizations due to behavioral crises, and a potential deceleration of the progression to costly long-term care facilities. While the initial cost of a novel, first-in-class medication may be a consideration, the long-term savings from reduced acute care and institutionalization could be substantial. This approval also signals the FDA’s continued commitment to addressing complex neurological and psychiatric conditions, encouraging further research and development in an area that has historically seen limited therapeutic breakthroughs.<\/p>\n Pharmaceutical Landscape and Future Research:<\/strong> Auvelity’s success as a non-antipsychotic treatment for agitation could spur greater investment and innovation in developing targeted therapies for other neuropsychiatric symptoms of dementia, such as apathy, depression, and psychosis, without relying on broad-spectrum psychotropics. This approval validates the exploration of novel mechanisms of action beyond traditional neurotransmitter systems, paving the way for a new generation of treatments. While Auvelity addresses a critical symptom, the medical community continues its relentless pursuit of disease-modifying therapies that can slow or halt the progression of Alzheimer’s disease itself. The progress in symptomatic treatment, however, is a vital step in improving the daily lives of those affected.<\/p>\n Axsome Therapeutics is preparing for the commercial launch of Auvelity, making it available to patients and clinicians in the near future. This launch will be accompanied by educational initiatives to ensure healthcare providers are well-informed about the drug’s mechanism, efficacy, and safety profile, enabling appropriate patient selection and management.<\/p>\n In conclusion, the FDA’s approval of Auvelity for agitation associated with Alzheimer’s disease represents a significant stride forward in dementia care. By providing a first-in-class, non-antipsychotic treatment with a distinct mechanism of action and a favorable safety profile, Auvelity offers renewed hope for millions grappling with the challenging realities of Alzheimer’s. It addresses a critical unmet medical need, promising to improve the quality of life for patients and alleviate the immense burden on their caregivers, marking a new chapter in the ongoing fight against this devastating disease.<\/p>\n","protected":false},"excerpt":{"rendered":" The U.S. Food and Drug Administration (FDA) has granted approval for Auvelity (dextromethorphan-bupropion) as a novel, first-in-class treatment specifically targeting agitation associated with Alzheimer\u2019s disease. This landmark decision marks a pivotal moment for millions of patients, their families, and caregivers, offering a therapeutic option that operates through a distinct mechanism of action, thereby circumventing the …<\/p>\n","protected":false},"author":1,"featured_media":5515,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39],"tags":[458,53,40,1209,674,1208,36,43,41,269,397,42,223],"newstopic":[],"class_list":["post-5516","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-alzheimers-dementia-care","tag-agitation","tag-alzheimer","tag-alzheimers","tag-antipsychotic","tag-approves","tag-auvelity","tag-class","tag-cognitive-health","tag-dementia-care","tag-disease","tag-first","tag-memory-care","tag-treatment"],"_links":{"self":[{"href":"https:\/\/homecares.net\/index.php?rest_route=\/wp\/v2\/posts\/5516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/homecares.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/homecares.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/homecares.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/homecares.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5516"}],"version-history":[{"count":0,"href":"https:\/\/homecares.net\/index.php?rest_route=\/wp\/v2\/posts\/5516\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/homecares.net\/index.php?rest_route=\/wp\/v2\/media\/5515"}],"wp:attachment":[{"href":"https:\/\/homecares.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/homecares.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/homecares.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5516"},{"taxonomy":"newstopic","embeddable":true,"href":"https:\/\/homecares.net\/index.php?rest_route=%2Fwp%2Fv2%2Fnewstopic&post=5516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"FDA](\"https:\/\/alzheimersnewstoday.com\/wp-content\/uploads\/2024\/04\/Megaphone_700x350.png\")
<\/figure>\n![\"FDA](\"https:\/\/alzheimersnewstoday.com\/wp-content\/uploads\/2022\/03\/thumbsup_700x350-150x0-c-default.png\")
<\/figure>\n